Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Contract manufacturing

Similar metrics at other companies

Vir Biotechnology, Inc. logo
VIRReportable Segment — Contract manufacturing
$23.97M+70.4%
Cadence Design Systems logo
CDNSReportable Segment — Manufacturing costs
$104.48M+3.0%
Vaxcyte, Inc. logo
PCVXReportable Segment — Acquired manufacturing rights
$0—
IPG Photonics logo
IPGPReportable Segment — Other manufacturing expenses
$36.84M+19.3%
SiTime Corporation logo
SITMReportable Segment — Other manufacturing overheads
$6.37M+7.1%
Ouster logo
OUSTReportable Segment — Product manufacturing costs
$22.5M+43.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inbx:ResearchAndDevelopmentExpenseContractManufacturing.

The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.

Filed
Mar 19, 2026, 4:00 PM EDT
Fiscal year
FY2025
Accession
0002007919-26-000006
Line itemYEAR ENDEDDECEMBER 31, 2025YEAR ENDEDDECEMBER 31, 2024
Research and development expense
Personnel35,37272,790
Clinical trials35,33947,665
Contract manufacturing19,59055,643
Equipment, depreciation, and facility10,2279,693
Other research and development12,50017,952
General and administrative expense
Merger-related—68,061

Item 8. Financial Statements and Supplementary Data.

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — contract manufacturing?
Inhibrx Biosciences, Inc. (INBX) reported business segments — contract manufacturing of $4.9M in Q4 2025.
How has Inhibrx Biosciences, Inc.'s business segments — contract manufacturing changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — contract manufacturing decreased by 64.8% year-over-year, from $13.91M to $4.9M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — contract manufacturing?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — contract manufacturing has grown at a -49.6% compound annual growth rate (CAGR), from $77.25M to $19.59M.
What does business segments — contract manufacturing mean?
Reflects the expenses paid to third-party organizations for the manufacturing and production of biologic therapeutic candidates. This metric highlights the company's reliance on external manufacturing partners to scale production for clinical or commercial needs.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — contract manufacturing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude